BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) fell 5.36% after reporting a net loss of (-$12) million for the three months ended September 30, 2017. However, the results exceeded Wall Street expectations as revenue increased 29% compared to the second quarter.
The stock is currently trading at a key support level of $2.65, below which it could drop to the next support level at $2.20. BioDelivery Sciences has come under pressure in recent weeks after touching highs of $3.40 a share. Observers are keen to see if the third quarter financial results is the catalyst that will help push the stock up.
According to the Chief Executive Officer, Mark Sirgo, the solid performance in the quarter was because of the strong sales momentum behind lead product BELBUCA.
“Our solid performance in the third quarter continued the encouraging trend we have seen with BELBUCA, as we achieved prescription growth of 15% over the second quarter. The favorable trend continued into October as BELBUCA monthly total prescriptions reached an all-time high in excess of 8,000 based on preliminary sales data,” said Mr. BELBUCA.
The executive expects continued growth of BELBUCA going forward due to a new sales strategy and improved managed care involving Medicare. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has also completed an important licensing agreement with Purdue Pharma for BELBUCA.
Q3 Financial Results
Net Revenue for the three months ended September 30, 2017, came in at $11.3 million, up from $3.6 million reported in the third quarter of 2016. BELBUCA and BUNAVAIL revenue totaled $6.4 million and $1.7 million respectively. Net revenue for the first nine months of the year totaled $49.5 million compared to $11.6 million in the same period last year.
Total operating expenses for the quarter was $16.9 million compared to $16.5 million reported last year. Net loss decreased to (-$12 million) or (-$0.21) a share compared to a net loss of (-$16) million or (-$0.30) a share, reported last year. The decrease in net loss was primarily attributed to net profitability from the reacquisition of BELBUCA early in the year.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has cash and cash equivalents of $19.7 million compared to $27.5 million as of June 30, 2017. During the quarter, the company met the financial requirements needed to access the next $15 million tranche in its loan agreement with CRG.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $BDSI and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.